Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Average Rating of "Buy" from Brokerages

Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) has received an average rating of "Buy" from the nine research firms that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, six have given a buy rating and two have assigned a strong buy rating to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $18.75.

A number of equities analysts recently weighed in on LXEO shares. JPMorgan Chase & Co. decreased their price objective on shares of Lexeo Therapeutics from $12.00 to $9.00 and set an "overweight" rating for the company in a report on Thursday, June 25th. Wall Street Zen raised shares of Lexeo Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, May 16th. Chardan Capital raised Lexeo Therapeutics to a "strong-buy" rating in a report on Tuesday, July 28th. Finally, Weiss Ratings downgraded shares of Lexeo Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a report on Thursday, July 30th.

Insider Transactions at Lexeo Therapeutics

In related news, CEO Richard Nolan Townsend sold 25,947 shares of the stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $4.48, for a total transaction of $116,242.56. Following the completion of the sale, the chief executive officer owned 377,817 shares in the company, valued at approximately $1,692,620.16. This trade represents a 6.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Narinder Pal Bhalla sold 22,306 shares of Lexeo Therapeutics stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $4.42, for a total value of $98,592.52. Following the sale, the insider directly owned 82,194 shares in the company, valued at $363,297.48. This trade represents a 21.35% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 62,204 shares of company stock worth $280,089. Insiders own 2.00% of the company's stock.

Institutional Investors Weigh In On Lexeo Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Allworth Financial LP lifted its holdings in shares of Lexeo Therapeutics by 1,002.9% in the fourth quarter. Allworth Financial LP now owns 3,386 shares of the company's stock worth $34,000 after buying an additional 3,079 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in Lexeo Therapeutics by 69.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,547 shares of the company's stock valued at $35,000 after acquiring an additional 1,459 shares in the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in Lexeo Therapeutics during the fourth quarter valued at $37,000. California State Teachers Retirement System increased its holdings in Lexeo Therapeutics by 123.7% in the 4th quarter. California State Teachers Retirement System now owns 3,884 shares of the company's stock valued at $39,000 after acquiring an additional 2,148 shares during the last quarter. Finally, Russell Investments Group Ltd. increased its holdings in Lexeo Therapeutics by 160.2% in the 4th quarter. Russell Investments Group Ltd. now owns 5,872 shares of the company's stock valued at $58,000 after acquiring an additional 3,615 shares during the last quarter. 60.67% of the stock is owned by hedge funds and other institutional investors.

Lexeo Therapeutics Stock Performance

Lexeo Therapeutics stock opened at $4.81 on Monday. The stock's 50 day simple moving average is $4.63 and its two-hundred day simple moving average is $5.71. The stock has a market cap of $377.68 million, a price-to-earnings ratio of -3.32 and a beta of 1.46. Lexeo Therapeutics has a fifty-two week low of $3.99 and a fifty-two week high of $10.99.

Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.29) by $0.04. On average, analysts predict that Lexeo Therapeutics will post -1.18 earnings per share for the current year.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source